The EGFR inhibitor cetuximab is the only molecularly targeted agent to show significant survival benefits in HNSCC patients as monotherapy or in combination with radiation and/or chemotherapy [9], [12], [13]. Here, EGFR is linked to head and neck squamous cell carcinoma.